NCT Number: NCT03131531
This registry has been established to gain a better understanding of the clinical and biological characteristics and outcome of patients with lymphoid cancer
Interested in participating?
Request Info18 year and older
All sexes
Observational
Bergamo, 24127, Italy
Location status: Recruiting
Alessandro Rambaldi, MD
PRINCIPAL_INVESTIGATOR
Giuseppe Gritti, MD, PhD
CONTACT
Giuseppe Gritti, MD, PhD
SUB_INVESTIGATOR
Lymphoid cancer including Hodgkin disease, non-Hodgkin lymphomas (NHL) and myeloma, represents the most common hematologic malignancy. Despite the overall prognosis improved in the last 10 years, there are many open issues that need to be addressed, specifically refractoriness to standard treatment, disease recurrence and outcome with new drug in the so called "real world" setting. Since the Hematology and Bone Marrow Transplant Unit at "Ospedale Papa Giovanni XIII" of Bergamo has developed specific tools to collect clinical data thought fully validated electronic charts and biological specimens thanks to a regulatory compliant biobanking program, the aim of this study is to collect clinical and biological information of lymphoid cancer patients. The cohort of patients enrolled will permit to analyze the practice pattern, perform biological correlative studies of great translational potential with relevance to clinical practice.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Clinical data, specific procedures and treatments will follow the Institutional standard operative procedures
Time frame: 20 years
Analyzed for all patients as time from diagnosis to death as a result of any cause, stratified according to intervention and baseline characteristics
Time frame: 20 years
Analyzed only for patients in complete response, as time from achievement of the complete response to relapse or death due to disease or acute toxicity of treatment, stratified according to intervention and baseline characteristics
Time frame: 20 years
Analyzed for all patients, as time from diagnosis to progression of disease or death as a result of any cause, stratified according to intervention and baseline characteristics
Time frame: 20 years
Association between clinical and biologic characteristics
Contact information is provided by the study sponsor or research team.
Alessandro Rambaldi, MD
CONTACT
Giuseppe Gritti, MD, PhD
CONTACT
A.O. Ospedale Papa Giovanni XXIII
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05065866
Hematologic Diseases, Hemic and Lymphatic Diseases
Tampa, Florida, United States
View Trial DetailsNCT04935684
Acute Leukemia in Remission, Bone Marrow Diseases
Amiens, France
View Trial DetailsNCT03050268
AML, Abnormalities, Multiple
Memphis, Tennessee, United States
View Trial DetailsNCT06131801
ALL, AML
Aurora, Colorado, United States
View Trial Details